Recent happy accidents in clinical research
The legendary painter Bob Ross used to tell his viewers, “We don’t make mistakes, just happy accidents.” In the world of clinical research, we don’t always share that optimism – we often treat the unexpected as a headache. A side effect that wasn’t predicted or a result that skews the data can feel like a setback, but from time to time, we have also seen these statistical outliers become canvas-changing breakthroughs.
There have been plenty of significant discoveries in medical history that didn’t come from a straight line between hypothesis and result. The past few years have continued this trend with a new wave of pivotal moments that are contributing to the evolution of drug development and trial design. Here are a few “happy accidents” we’ve seen recently in clinical research that are changing the industry.
SGLT2 Inhibitors: Diabetes to Heart Failure
A significant clinical shift of the 2020s involves SGLT2 inhibitors, like empagliflozin. These were designed solely for glycemic control in people with diabetes. However, during mandatory cardiovascular safety trials, researchers found the drugs were effective at preventing heart failure hospitalizations.
This discovery was so profound that by 2023, SGLT2 inhibitors became a pillar of heart failure treatment, regardless of whether the patient has diabetes or not. The drugs’ goals, originally targeting a metabolic population, have been expanded to include a massive cardiovascular population as well.
The drugs now cover more bases than initially intended, demonstrating the flexibility and multifunctionality we can find in certain medicines.
Lixisenatide: T2D to Parkinson’s
Lixisenatide, originally a drug for type 2 diabetes, showed a surprising effect in clinical trials: it appeared to slow the progression of motor symptoms in patients with Parkinson’s disease.
A phase 2 trial published in 2024 revealed that patients on the drug showed no worsening of motor symptoms over a year, while those on placebo did. This triggered a surge in recruitment interest for metabolic-neurology crossover trials, which have so far shown mixed results. The connection is there, but more research is needed.
Formoterol: Asthma to Liver Disease
Just this May, a research team at the Medical University of South Carolina announced a surprising discovery. Formoterol, a standard bronchodilator that has been used to treat asthma for decades, has significantly lowered levels of liver fat and damage in mice.
The team believes this discovery could open a potential indication for MASH (Metabolic Dysfunction-Associated Steatohepatitis), a form of fatty liver disease. This could be a big change; we are potentially looking at shifting a well-known respiratory medication into a crowded and urgent metabolic disease space.
In the clinical research and trial recruitment space, these stories are more than just fun facts: they highlight why patient data and observation outside of expected parameters are so critical. Over the years we’ve learned to never ignore the outliers – unexpected results could lead to a change in direction or even a breakthrough.
At Praxis, we understand the nuances of the research journey, from the first protocol draft to the unexpected pivots. If you’re looking for a partner who can navigate the complexities of recruitment, let’s connect!
